418 related articles for article (PubMed ID: 22040439)
21. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.
Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY
Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797
[TBL] [Abstract][Full Text] [Related]
22. Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation.
Xu Q; Xu B; Zhang Y; Yang J; Gao L; Zhang Y; Wang H; Lu C; Zhao Y; Yin T
Thromb Haemost; 2012 Dec; 108(6):1132-40. PubMed ID: 23015069
[TBL] [Abstract][Full Text] [Related]
23. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
[TBL] [Abstract][Full Text] [Related]
24. Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes.
Moreau C; Pautas E; Gouin-Thibault I; Golmard JL; Mahé I; Mulot C; Loriot MA; Siguret V
J Thromb Haemost; 2011 Apr; 9(4):711-8. PubMed ID: 21255252
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy.
Kwon A; Jo SH; Im HJ; Jo YA; Park JY; Kang HJ; Kim HS; Cho HC; Lee YK
J Thromb Thrombolysis; 2011 Nov; 32(4):467-73. PubMed ID: 21713378
[TBL] [Abstract][Full Text] [Related]
26. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
Scott SA; Jaremko M; Lubitz SA; Kornreich R; Halperin JL; Desnick RJ
Pharmacogenomics; 2009 Aug; 10(8):1243-55. PubMed ID: 19663669
[TBL] [Abstract][Full Text] [Related]
27. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
28. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.
Kim HS; Lee SS; Oh M; Jang YJ; Kim EY; Han IY; Cho KH; Shin JG
Pharmacogenet Genomics; 2009 Feb; 19(2):103-12. PubMed ID: 19077919
[TBL] [Abstract][Full Text] [Related]
29. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
[TBL] [Abstract][Full Text] [Related]
30. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients.
You JH; Wong RS; Waye MM; Mu Y; Lim CK; Choi KC; Cheng G
J Thromb Thrombolysis; 2011 Jan; 31(1):113-8. PubMed ID: 20585834
[TBL] [Abstract][Full Text] [Related]
31. Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes.
Valentin II; Vazquez J; Rivera-Miranda G; Seip RL; Velez M; Kocherla M; Bogaard K; Cruz-Gonzalez I; Cadilla CL; Renta JY; Feliu JF; Ramos AS; Alejandro-Cowan Y; Gorowski K; Ruaño G; Duconge J
Ann Pharmacother; 2012 Feb; 46(2):208-18. PubMed ID: 22274142
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
Beinema M; Brouwers JR; Schalekamp T; Wilffert B
Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
[TBL] [Abstract][Full Text] [Related]
33. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.
Schalekamp T; Brassé BP; Roijers JF; Chahid Y; van Geest-Daalderop JH; de Vries-Goldschmeding H; van Wijk EM; Egberts AC; de Boer A
Clin Pharmacol Ther; 2006 Jul; 80(1):13-22. PubMed ID: 16815313
[TBL] [Abstract][Full Text] [Related]
34. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.
Sconce EA; Khan TI; Wynne HA; Avery P; Monkhouse L; King BP; Wood P; Kesteven P; Daly AK; Kamali F
Blood; 2005 Oct; 106(7):2329-33. PubMed ID: 15947090
[TBL] [Abstract][Full Text] [Related]
35. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F
Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826
[TBL] [Abstract][Full Text] [Related]
36. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes.
Wen MS; Lee M; Chen JJ; Chuang HP; Lu LS; Chen CH; Lee TH; Kuo CT; Sun FM; Chang YJ; Kuan PL; Chen YF; Charng MJ; Ray CY; Wu JY; Chen YT
Clin Pharmacol Ther; 2008 Jul; 84(1):83-9. PubMed ID: 18183038
[TBL] [Abstract][Full Text] [Related]
37. Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.
Linder MW; Bon Homme M; Reynolds KK; Gage BF; Eby C; Silvestrov N; Valdes R
Clin Chem; 2009 Oct; 55(10):1861-8. PubMed ID: 19679631
[TBL] [Abstract][Full Text] [Related]
38. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes.
Zhu Y; Shennan M; Reynolds KK; Johnson NA; Herrnberger MR; Valdes R; Linder MW
Clin Chem; 2007 Jul; 53(7):1199-205. PubMed ID: 17510308
[TBL] [Abstract][Full Text] [Related]
39. The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement.
Tatarūnas V; Lesauskaitė V; Veikutienė A; Jakuška P; Benetis R
Medicina (Kaunas); 2011; 47(1):25-30. PubMed ID: 21681008
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetic tests could be helpful in predicting of VKA maintenance dose in elderly patients at treatment initiation.
Kovac MK; Rakicevic LB; Kusic-Tisma JS; Radojkovic DP
J Thromb Thrombolysis; 2013 Jan; 35(1):90-4. PubMed ID: 22763922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
